
It could be a costly affair for Novo Nordisk to secure approval of their long-acting insulin, Tresiba, in the US.
The FDA will review the risk of cardiovascular complications when their expert panel meets on the 8th of November to assess Tresiba. According to the FDA, Tresiba is associated with an increased risk of cardiovascular incidents compared with similar products.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app